MENU

FIND DOCTORS

Name: Wu Jiong
Department: BREAST SURGERY
Title:Professor, Vice president

 
 
Education & Professional Experience   2005-present Executive committee member and secretary, Specialty Branch of Breast Cancer, Chinese Anticancer Association 
2002-present Committee member, Specialty Branch of Soft Tissue Tumor, Chinese Anticancer Association
2001-present Associate Professor, Department of Breast Surgery, Cancer Hospital/Institute, Fudan University, Shanghai
1999-present Secretary of Breast Cancer Prevention and Treatment Group, 
Disease Prevention and Control Center of Shanghai 
1999-present Committee member, Specialty Branch of Breast Cancer, Chinese Anticancer Association
1999-Dec, 1999 Attending doctor of Surgical Oncology, Medical Center of FenXian County, Shanghai.
1998-2001 Attending doctor of Surgical Oncology, Cancer Hospital, Shanghai Medical University, Shanghai, P.R. China 
1993-1998 Postgraduate Course on Surgical Oncology, Shanghai Medical University, Shanghai, P.R. China 
1993-1998 Residency of Surgical Oncology, Cancer Hospital, Shanghai Medical University, Shanghai, P.R. China 
1987-1993 Doctor of Medicine (M.D. equivalent), Shanghai Medical University, Shanghai, P.R. China 
 
 
Specialty   His research interest is gene signature in breast cancer prognosis and prediction. As a breast surgeon, Dr. Wu focuses on breast cancer conservative surgery, sentinel lymph node biopsy and onco-plastic surgery involving immediate breast reconstruction, partial breast reconstruction.
 
 
Research   1993-1998
Studies on the apoptosis and related regulated gene (bcl-2, bcl-xl, Bax, p27kip1) expression in human breast cancer as related to prognosis.

1998-present
1.The prognosis of axillary lymph node negative breast carcinoma.
2.Early detection of breast cancer, especially the investigation of microcalcificate lesion of the breast.
3.Diagnosis of intraductal lesions with fibrous ductoendoscopy.
4.Sentinel lymph node biopsy in axillary node negative breast cancer.
 
 
Publication   1. Wu J, Jin H-M. Critical disease and Fibronectin. Foreign Medicine, Volume of Physiology, Pathology and Clinics, (Chinese) 1991, 11(4):173-175.
2. Wu J, Shen ZZ. Estrogen receptor and breast cancer. Chin Oncol, (Chinese)1995, 5(4):275-279.
3. Shao Z-M, Jiang M, Wu J, Han Q-X, Zhang T-Q, Shen Z-Z and Fonatan JA. Identification of spontaneous programmed cell death during development of human breast cancer. Oncology Reports, 1996, 3:1133-1136.
4. Shao Z-M, Jiang M, Wu J, Yu l-M, Han q-x, Zhang T-Q, Shen Z-Z. Inhibition of apoptosis in human breast cancer and apoptosis in human breast cancer as related to prognosis. Oncology Reports, 1996, 3:1183-1186.
5. Shao Z-M, Jiang M, Wu J, Yu L-M, Han Q-X, Zhang T-Q, Shen Z-Z. Inhibition of spontaneous apoptosis in human breast cancer. Chinese Med Sci J, 1996, 11(4): 200-203.
6. Wu J, Shi Y-Q, Shen Z-Z. Case report: Relapse of Dermato Fibro Sarcoma Protuberans inducing progression to fibroma. Chin Oncol, (Chinese) 1997, 7(4): 269.
7. Jiang M, Shao Z-M, Wu J, Lu J-S, Yu L-M, Han Q-X, Shen Z-Z,and Joseph A Fontana. p21/WAF1/CIP1 and MDM2 gene expression in human breast carcinoma patients as related to prognosis. Int J Cancer, 1997, 74:529-534.
8. Wu J, Shao Z-M, Jiang M, et al. In situ DNA labeling apoptosis in breast cancer as related to prognosis. Chin J Oncol, (Chinese)1997, 19(2):100-102.
9. Wu J,Shao zm, Shen ZZ. Apoptosis and breast cancer. Chin Oncol, (Chinese) 1997, 7(2):137-139.
10. Wu J, Shao Z-M, Jiang M, Han Q-X, Zhang T-Q, Shen Z-Z. In situ labeling apoptosis in breast cancer as related to prognosis. Chin J Cancer Res, 1997, 9(3): 213-216.
11. Jiang M, Shao Z-M, Zhang Y-W, Wu J, Han Q-X, Shen Z-Z. Study on p53, mdm-2 and p21WAF1 protein expression in ER-positive and ER-negative human breast cancer cell lines and its relation to biological features. Chin J Pathol, (Chinese)1997, 26(6): 327-330.
12. Wu J, Shen Z-Z. Study of bcl-2 gene family in human breast carcinoma. Chin Oncol, (Chinese)1998, 8(3): 217-221.
13. Shao Z-M, Wu J, Shen Z-Z, Barsky SH. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer, 1998, 18: 1435-1439.
14. Shao Z-M, Wu J, Shen Z-Z, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res, 1998, 58: 4851-4857.
15. Jiang M, Shao Z-M, Wu J, Lu J-S, Han Q-X, Shen Z-Z. WAF1/CIP1/p21 gene in wild type p53 and mutant p53 human breast cancer cell lines in relation to its cytobiological features. Chin J Oncol, (Chinese) 1998, 20(3): 181-184.
16. Shao Z-M, Li J, Wu J, Han Q-X, Shen Z-Z, Fontana JA, Barsky SH. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat, 1998, 53: 263-269.
17. Wu J, Shen Z-Z. Four cases of adenoma of nipple. Chin Oncol, (Chinese) 1998, 8(4): 318.
18. Wu J, Shen Z-Z, Shao Z-M. Prognostic significance of apoptosis and its related genes in human breast carcinoma. Shanghai Med J, (Chinese) 1999, 22(1): 27-31.
19. Wu J, Lu J-S, Jiang M, Han Q-X, Shen Z-Z, Fontana JA, Barsky SH, Shao Z-M. Prognostic role of the cell-cycle inhibitor p27Kip1 expression and spontaneous apoptosis in human breast cancer. Brit J Cancer, 1999, 79(9): 1572-1578.
20. Wu J, Shen Z-Z, Shao Z-M. Prognostic significance of cyclin-dependent kinase inhibitor p27kip1 expression in human breast cancer. Chin J Oncol, (Chinese) 1999, 21(4): 265-268.
21. Wu J, Shao Z-M, Jiang M, Han Q-X, Shen Z-Z. Apoptotic-related gene expression in the growth of breast carcinoma cell lines. Chin J Oncol, (Chinese) 1999, 21(6): 429.
22. Wu J, Lu J-S, Shao Z-M, Han Q-X, Shen Z-Z. Prognostic significance of apoptosis related gene family bcl-2 in human breast cancer tissues. J Shanghai Med Univ, (Chinese) 1999, 26(3): 165-168.
23. Wu J, Shao Z-M, Shen Z-Z, Lu J-S, Han Q-X, Fontana J-A, Barsky SH. Significance of Apoptosis and apoptotic-related proteins, Bcl-2, and Bax in primary breast cancer. The Breast J, 2000, 6(1): 44-52.
24. Wu J, Shao Z-M, Shen Z-Z. Current study of cyclin dependent kinase inhibitor p27kip1 in the prognosis of tumor. Chin Oncol, (Chinese) 2000, 10(1): 84-86.
25. Wu J, Lu J-S, Shao Z-M, et al. Prognostic significance of apoptosis related gene family bcl-2 in human breast cancer. Chin J Cancer Res, 2000, 12(1): 5-9.
26. Shen Z-Z, Wu J. Review and prospects of the treatment of breast carcinoma. Tumor, (Chinese)2000, 20(5): 315-318.
27. Shao Z-M, Wu J, Shen Z-Z. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Chin J Oncol, (Chinese)2000, 22(5): 362-365.
28. Shen KW, Wu J, Lu JS, et al. Fiberoptic ductoscopy for patients with nipple discharge. Cancer, 2000, 89(7): 1512-1519.
29. Wu J,Shen ZZ. Extended radical mastectomy, dispute and evaluation. Chin J Practical Surg, (Chinese)2001,21(1): 39-40.
30. Wu J,Shao ZM,Shen ZZ. Related problems in breast conservative surgery. J Surg Concepts Pract,(Chinese)2001,6(4): 262-264.
31. Lu JS, Shen ZZ, Wu J, et al. Analysis of the relationship between cell cycle related factors and carcinogenesis of breast cells and biological characteristics of breast cancer cells. Chin Oncol, (Chinese)2001,11(3): 193-195.
32. Lu JS, Shen ZZ, Wu J, et al. Protein expression of cyclin D1 and CDK4 in breast cancer as related to prognosis. Chin Oncol, (Chinese)2001,11(2): 105-108.
33. Wu J, Shao ZM, Zhang JX, et al. Breast-conserving therapy for patients with early stage breast carcinoma. Chin Oncol, (Chinese)2001,11(2): 131-134.
34. Shao ZM, Wu J, Shen ZZ, Nguyen M. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res. 2001 Aug;7(8):2222-7
35. Shen KW, Wu J, Lu JS, et al. Fiberoptic ductoscopy for breast cancer patients with nipple discharge. Surg Endosc. 2001, 15(11):1340-1345.
36. Chen CM, Wu J, Zhang JX, et al. Navelbine plus adriamycin regimen in neoadjuvant chemotherapy of locally advanced breast cancer. J Surg Concepts Pract, (Chinese)2001,6(4): 226-228.
37. Zhang J,Shen KW,Wu J,et al. Combined detection for micrometastasis in sentinel lymph node and in bone marrow in patients with breast cancer. J of Oncol, (Chinese) 2002, 8(6):328-331.
38. Zhang J, Shen K, Nirmal L, Liu G, Wu J, Zhang Y, Du H, Pan Z, Shao ZM, Shen ZZ. Lymphoscintigraphy in sentinel lymph node biopsy of breast cancer. Chin J Oncol. (Chinese), 2002, 24(6): 616-618.
39. Shen KW, Lamichhane N, Wu J, et al. Sentinal lymph node biopsy in breast cancer. Chin J Surg(Chinese), 2002, 40(5):347-350.
40. Wen XF, Shen ZZ, Wu J, et al. Study on the clinical value of estrogen receptor β protein detection in fresh human breast cancer samples Chinese Journal of Experimental Surgery, Chin J Exp Surg(Chinese), 2002, 19(1):27-28
41. Hu Z, Wu J, Lu JS, et al. Analysis of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Chin J Oncol. (Chinese), 2004, 26(11):657-659.
42. Wu J, Shao ZM , Shen KW, et al. Identifying factors related to bone metastasis in breast cancer chin oncol, (Chinese) 2003, 13(4): 316-318.
43. Liu G, Zhang J, Wu J, et al. Clinical significance of the circulating chemokines in breast carcinoma patients chin oncol, (Chinese) 2003, 13(4): 297-300.
44. Chen CM, Shen KW, Wu J, et al. The combination of navelbine and epirubicin as neoadjuvant chemotherapy in the treatment of locally advanced breast cancer. Chin Oncol. (Chinese)2003,13(4):310-313.
45. Di GH, Liu G, Wu J, et al. Peripheral blood mutated p53 DNA and clinical value in human breast cancer. Chin J Oncol. (Chinese)2003, 25(2):137-140.
46. LU JS, Liu G, Wu J, et al. Effect of green tea on VEGF expression and its mechanism in human breast cancer cells. Chin Exp Surg. (Chinese)2003,20(6):513-514.
47. Hu Z, Wu J, Lu JS, et al. Analysis of brca1 mutations in Chinese patients with early onset breast cancer and affected relatives. Chin J Oncol. (Chinese) 2004 26(11):657-659.
48. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene. 2004, 23(34): 5799-5806.
49. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004, 88(1): 75-85.
50. Liu GY, Shen KW, Zhang JX, Lu JS, Wu J, Shao ZM, Shen ZZ. Clinical practice of stereotactic core needle biopsy for breast leision. Tumor. (Chinese) 2004, 24(3):264-266.
51. Wu J, Shen ZZ. Current studies and evaluations of sentinel lymph node biopsy for breast cancer. Chin Oncol, (Chinese) 2005.15(5):417-421.
52. Huang XY, *Wu J. Evaluation of intraoperative touch imprint cytology diagnosis of sentinel lymph nodes in breast cancer. Chin Oncol, (Chinese) 2005.15(5):490-493
53. Dong HM, Liu G,WU J,et al. Effects of MAPK on a human inflammatory breast carcinoma cell line. Chin Oncol, (Chinese) 2005.15(5): 426-428.
54. Hou YF,Yuan ST,LI HC,Wu J,et al. In vitro study of the effects of estrogen receptorβexpression on the biological behavior of a human breast cancer cell line . Chin J Oncol. (Chinese) 2005, 27(7): 389-392.
55. Fan J, Wu J, Lu JS, et al. Breast conserving therapy in stage T1 and T2 breast cancer patients. Chin J Cancer Res. 2005,17( 2):137-139.
56. Liu ZB, *Wu J. Current studies in internal mammary sentinel lymph node biopsy of breast cancer. Chin J Surg, (Chinese) 2006, 44(19): 1357-1359.
57. Wu J, Fan J, Lu JS, et al. Clinical analysis of efficacy and cosmetic results in 234 early breast cancer patients with breast-conserving treatment. Chin Oncol, (Chinese) 2006, 16(9): 697-700.
58. Wang L, Li DQ, WU J, et al. Analysis of differential proteins expression in human breast cancer cell lines with differently metastatic potential by real-time RT-PCR and immunohistochemistry. Chin J Oncol. (Chinese) 2006, 16(9): 706-709.
59. Yu KD, DI GH, Wu J, et al. The Predictive Value of Progesterone Receptor Status for Adjuvant Endocrine Therapy for Aged Patients with Breast Cancer. Chin J Clin Oncol. 2006, 33(17): 999-1002.
60. Fan J, Wang L, Wang XJ, Wu J, Lu JS, Di GH, Shen KW, Han QX, Liu BL, Shen ZZ, Shao ZM. Breast conservative therapy in east part of China: a retrospective cohort study. J Cancer Res Clin Oncol. 2006, 132(9):573-578.
61. Di GH, Yu KD, Wu J, et al. Immediate breast reconstruction with latissimus dorsi musculocutaneous flap: a suitable option for Chinese women after mastectomy. Chin J Cancer Res. 2006, 18(2): 88-93.
62. Chen CM, Shen KW, Liu GY, Wu J, Lu JS, Zhuang CJ, Han QX, Liu BL, Shao ZM, Shen ZZ. A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer. Chin J Surg. (Chinese) 2006, 44(11):745-747.
63. Yu KD, Di GH, Wu J, et al. Clinical and pathologic analysis of primary bilateral breast cancer: a report of 103 cases. Chin Oncol, (Chinese) 2006, 16(5):362-366.
64. Fan J, Lu JS, Wang L, Wu J, et al. The study on chemical suppression of proliferation of MDA-MB-435 through AZA and TSA. Chin Oncol, (Chinese) 2006, 16(5):329-332.
65. Gu YJ, Xiao Q, Wu J, et al. Mammographic follow-up after conservation therapy for breast cancer. Chin J Radiol(Chinese), 2006, 40(4):344-349.
66. DI GH, Wu J, QI FZ, et al. Immediate breast reconstruction after mastectomy of breast cancer. Chin Oncol, (Chinese) 2006, 16 (4): 257-261.
67. Dong HM, Liu G, Wu J, et al. Biological significance of E-cadherin in an inflammatory breast carcinoma cell line. Chin J Oncol. (Chinese), 2006, 28(1): 4-7.
68. Huang XY,Wu J*,Xu WP,et al. Evaluation of intraoperative touch imprint cytology of sentinel lymph node for breast cancer. Chin J Oncol (Chinese),2007,29(8): 596-599.
69. Liu ZB,Wu J*,Huang XY,et al. Methylene blue dye versus combined blue dye-radioactive tracer in the detection of sentinel lymph node in breast cancer. Chin J Gen Surg (Chinese),2007,22(11): 840-843.
70. Huang XY,Wu J*,Liu ZB,et al. Application of methylene blue dye to sentinel lymph node biopsy in breast cancer and its influencing factors. Chin J Cancer (Chinese),2007,26(10): 1133-1137.
71. Jin W, Di GH, Li JJ, Chen Y, Li WF, Wu J, et al. TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS Letters, 2007, 581: 3826-3832.
72. Jin W, Wu J#, Li JJ, Fei F, et al. Gene expression profiling in apoptotic K562 cells treated by homoharringtonine. Acta Biochimica et Biophysica Sinica, 2007, 39(12): 982-991.
73. Wu J, Di GH, Chen TW, et al. A retrospective study of 129 cases with immediate breast reconstruction after skin-sparing mastectomy for breast cancer. Chin J Surg(Chinese), 2008, 46(10): 737-740.
74. Liu ZB,Wu J*,Pin B,et al. Expression of CK5/6 and CK 17 and its correlation with prognosis of triple-negative breast cancer patients. Chin J Oncol(Chinese),2008,30(8): 610-614.
75. Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J*. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncol Reports, 2008, 20: 987-994.
76. Liu ZB, Wu J*, Pin B, et al. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype. Tumori, 2009, 95: 53-62.
77. Chen JJ, Huang XY, Liu ZB, Chen TW, Chen JY, Yang WT, Xu WP, Shao ZM, Shen ZZ, Wu J*. Sentinel node biopsy and quality of life measures in a Chinese population. Eur J Surg Oncol, 2009, 35: 921-927.
78.

*Corresponding author
#Co-first author
 
 
Awards   •1992, 1995, 1997
Best student in Shanghai Medical University.
•1997
Bao-Gang scholarship issued by graduate institute, Shanghai Medical University.
•Jan.-Apr. 1998
UICC(International Union Against Cancer) ICRETT (International Cancer Technology Transfer) fellowship. Study the effect of myoepithelial cell paracrine on human breast cancer cell growth and infiltration, at UCLA Medical School/Relvon Breast Cancer Center.
•Jan, 2000
Shanghai, Bureau of Health, “New Star of Medicine”Award, 2000-2002, RMB 160,000.
•Shanghai, Bureau of Health Award, 2003-2005. A mathematical model predicting breast cancer risk. RMB 30,000.
•Shanghai Scientific Committee Award, ERβexpression in breast carcinoma and its effect on proliferation and metastasis. RMB 110,000.
•Shanghai Scientific Committee Award, Sentinel lymph node biopsy in breast cancer. RMB 200,000.
•Shanghai Educational Committee Award, A prospective study of sentinel lymph node biopsy in breast cancer. RMB 120,000.
 
 
Out-patient Schedule  

Monday Morning